Acquired Thrombotic Thrombocytopenic Purpura (aTTP) is a rare disease that, when left untreated leads to a 95% morbidity rate. However, 80-90% of patients that receive treatment respond favorably. In this Phase III study, Pharm-Olam International is partnering with a progressive sponsor company to assist in finding a better solution for suffering
with aTTP.

Study Overview:

A Phase III study for the treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Sites & Locations:

91+ Sites across 25 countries in Asia, Eastern and Western Europe and North America

Services Provided:

• Site Identification & Selection
• Regulatory
• Clinical & Medical Monitoring
• Project Management
• Medical Writing

Learn the details by clicking on the image on the right.